Business Description
Kymera Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US5015751044
Share Class Description:
KYMR: Ordinary SharesTotal Employee Number:
253Description
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.09 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.26 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 40.14 | |||||
Beneish M-Score | -3.39 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -18.8 | |||||
3-Year EBITDA Growth Rate | -8.4 | |||||
3-Year EPS without NRI Growth Rate | -8.3 | |||||
3-Year FCF Growth Rate | 1.4 | |||||
3-Year Book Growth Rate | 29.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -7.48 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.82 | |||||
9-Day RSI | 71.39 | |||||
14-Day RSI | 69.99 | |||||
3-1 Month Momentum % | 0.74 | |||||
6-1 Month Momentum % | -0.68 | |||||
12-1 Month Momentum % | 76.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.81 | |||||
Quick Ratio | 10.81 | |||||
Cash Ratio | 10.39 | |||||
Days Sales Outstanding | 283.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.9 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -690.19 | |||||
Net Margin % | -611.96 | |||||
EBITDA Margin % | -595.16 | |||||
FCF Margin % | -474.01 | |||||
OCF Margin % | -471.26 | |||||
ROE % | -27.05 | |||||
ROA % | -24 | |||||
ROIC % | -51.86 | |||||
3-Year ROIIC % | -26.89 | |||||
ROC (Joel Greenblatt) % | -351.58 | |||||
ROCE % | -25.38 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 193.42 | |||||
PB Ratio | 5.77 | |||||
Price-to-Tangible-Book | 5.77 | |||||
EV-to-EBIT | -26.45 | |||||
EV-to-EBITDA | -27.17 | |||||
EV-to-Revenue | 161.69 | |||||
EV-to-Forward-Revenue | 104.83 | |||||
EV-to-FCF | -34.11 | |||||
Price-to-GF-Value | 4.76 | |||||
| Price-to-Net-Current-Asset-Value | 16.21 | |||||
| Price-to-Net-Cash | 17.03 | |||||
Earnings Yield (Greenblatt) % | -3.78 | |||||
FCF Yield % | -2.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KYMR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kymera Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 51.475 | ||
| EPS (TTM) ($) | -3.57 | ||
| Beta | 2.345 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.7 | ||
| Volatility % | 62.93 | ||
| 14-Day RSI | 69.99 | ||
| 14-Day ATR ($) | 6.824004 | ||
| 20-Day SMA ($) | 86.3445 | ||
| 12-1 Month Momentum % | 76.7 | ||
| 52-Week Range ($) | 36.65 - 130.05 | ||
| Shares Outstanding (Mil) | 82.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kymera Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kymera Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 131 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 130 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 08:30 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 45 days | ||
| General meeting for 2026 | 2026-06-24 08:30 | 98.25 (+0.49%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:10 | 71.29 (-7.88%) | ||
| Guidance call for 2026 | 2026-05-19 09:00 | 79.67 (-3.32%) | ||
| Guidance call for 2026 | 2026-05-12 09:20 | 84.10 (-2.19%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:30 | 81.51 (-1.16%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 81.51 (-1.16%) |
Show
Entries
Kymera Therapeutics Inc Frequently Asked Questions
What is Kymera Therapeutics Inc(KYMR)'s stock price today?
The current price of KYMR is $108.12. The 52 week high of KYMR is $130.05 and 52 week low is $36.65.
When is next earnings date of Kymera Therapeutics Inc(KYMR)?
The next earnings date of Kymera Therapeutics Inc(KYMR) is 2026-08-11 Est..
Does Kymera Therapeutics Inc(KYMR) pay dividends? If so, how much?
Kymera Therapeutics Inc(KYMR) does not pay dividend.
Guru Commentaries on NAS:KYMR
No articles.
Press Release
Articles on Kymera Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 11, 2026
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Seeking Alpha • 1:36pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers